Goldline Pharmaceutical
· SME · BSE
Price Band
₹41–43
Lot Size
3000 shares
Issue Size
₹12 Cr
Min. Investment
₹1,29,000
Grey Market Premium
Indicative, updates through the day
Estimated listing price: ₹43
Subscription Status
Subscription data will appear once bidding opens.
About Goldline Pharmaceutical
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments: The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations. All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply. The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Issue Objectives
- Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company
- General Corporate Purposes
- Issue Expense
Anchor Investors
Goldline Pharmaceutical IPO raises ₹3.15 crore from anchor investors. Goldline Pharmaceutical IPO Anchor bid date is May 11, 2026.
Reservation
| Category | Shares Offered | % |
|---|---|---|
| QIB | 12,72,000 | 49.65% |
| − Anchor Investor | 7,32,000 | 0% |
| − QIB (Ex. Anchor) | 5,40,000 | 0% |
| NII (HNI) | 3,90,000 | 15.22% |
| − bNII > ₹10L | 2,58,000 | 0% |
| − sNII < ₹10L | 1,32,000 | 0% |
| Retail | 9,00,000 | 35.13% |
| Market Maker | 1,38,000 | 0% |
- QIB49.6%
- − Anchor Investor0.0%
- − QIB (Ex. Anchor)0.0%
- NII (HNI)15.2%
- − bNII > ₹10L0.0%
- − sNII < ₹10L0.0%
- Retail35.1%
- Market Maker0.0%
Market Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 6000 | ₹2,58,000 |
| Individual investors (IND) (Max) | 2 | 6000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 9000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 21000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 24000 | ₹10,32,000 |
Financials (₹ Cr)
Valuations
EPS (Pre IPO)
4.11
EPS (Post IPO)
3.09
ROE
17.99%
P/E (Pre IPO)
10.47
P/E (Post IPO)
13.93
Price / Book
Market Cap
₹41.28 Cr.
Peers Comparison
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Speciality Medicines Ltd. | 9.27 | ₹29.14 Cr | |
| Accretion Nutraveda Ltd. | 26.27 | ₹24.77 Cr | |
| KRM Ayurveda Ltd. | 17.32 | ₹77.49 Cr | |
| Curis Lifesciences Ltd. | 12.44 | ₹27.52 Cr | |
| Aptus Pharma Ltd. | 11.29 | ₹13.02 Cr | |
| Asston Pharmaceuticals Ltd. | 17.83 | ₹27.56 Cr |
Contact Details
Goldline Pharmaceutical Ltd. Address
- +91 712 2786666
- info@goldlinepharma.in
- https://www.goldlinepharma.in/
Registrar Contact Details
Bigshare Services Pvt. Ltd.
- +91 22 6263 8200
- ipo@bigshareonline.com
- https://bigshareonline.com
- Office No. S6-2, 6th Floor, Pinnacle Business Park, Andheri East, Mumbai – 400093
Frequently Asked Questions
Key Dates
- Open Date
- 12 May 2026
- Close Date
- 14 May 2026
- Listing Date
- 19 May 2026
Issue Details
- Registrar
- Bigshare Services
- Lead Manager(s)
- Exchange
- BSE